Clinically isolated syndrome (CIS) usually describes a first clinical episode that suggest multiple sclerosis. One of the signs and symptoms of CIS is Optic neuritis (ON). Several early intervention drugs are being tested in clinical trials for the early intervention in CIS patients which may lead to multiple sclerosis (MS). This study aim (1) early intervention of the CIS progression to MS delay slow down the MS progression, (2) since that ON affects 30%–70% of MS patients, the available ON intervention delay the MS progression. PubMed was used as a search engine. Summary relative risks (RRs) and 95 % confidence intervals (CIs) were estimated using a random-effect model. For aim 1, it showed lower risk of progression to MS compared to non-treated group (Risk Ratio (RR) 0.64; 95%CI: 0.58, 0.69; p < 0.001). For aim 2, drug treated group showed lower risk of progression compared to non-treated group (RR 0.19, 95%CI: 0.06, 0.54, p < 0.002. Statistical heterogeneity was not significant in both outcomes and bias of publication was not found using inspection of funnel plot and Egger’s statistical test in both outcomes. In conclusion, early treatment should be considered in CIS patients to prevent the progression of MS. Moreover, this data shows that early intervention (Erythropoietin, Ery) of ON decreases the conversion risk to MS.
LaveryAMVerheyLHWaldmanAT.Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int2014; 2014: 262350.
MillerDBarkhofFMontalbanX, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol2005; 4(5): 281–288.
4.
FrohmanEMFujimotoJGFrohmanTC, et al. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol2008; 4(12): 664–675.
5.
FisnikuLKBrexPAAltmannDR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131(Pt 3): 808–817.
6.
BrexPAO’RiordanJIMiszkielKA, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology1999; 53(6): 1184–1190.
7.
O’RiordanJIThompsonAJKingsleyDP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain1998; 121(Pt 3): 495–503.
8.
BarkhofFFilippiMMillerDH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain1997; 120(Pt 11): 2059–2069.
9.
RoccaMAAgostaFSormaniMP, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol2008; 255(5): 683–691.
10.
LiuYDuanYYuC, et al. Clinical isolated syndrome: a 3-year follow-up study in China. Clin Neurol Neurosurg2011; 113(8): 658–660.
11.
TintoreMRoviraAMartinezMJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol2000; 21(4): 702–706.
12.
BrexPAMiszkielKAO’RiordanJI, et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry2001; 70(3): 390–393.
13.
JacobsLDWendeKEBrownscheidleCM, et al. A profile of multiple sclerosis: the New York state multiple sclerosis consortium. Mult Scler1999; 5(5): 369–376.
14.
OrtonSMHerreraBMYeeIM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol2006; 5(11): 932–936.
15.
WeinshenkerBGBassBRiceGP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain1989; 112(Pt 1): 133–146.
BatesD.Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology2011; 76(1 Suppl 1): S14–S25.
18.
PolmanCHReingoldSCEdanG, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann Neurol2005; 58(6): 840–846.
19.
Martinelli BoneschiFRovarisMComiG, et al. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Mult Scler2004; 10(4): 341–347.
20.
SchwenkenbecherPWursterUKonenFF, et al. Impact of the McDonald criteria 2017 on early diagnosis of relapsing-remitting multiple sclerosis. Front Neurol2019; 10: 188.
21.
KurtzkeJF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33(11): 1444–1452.
22.
van MunsterCEUitdehaagBM. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs2017; 31(3): 217–236.
23.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol2009; 62(10): e1–e34.
24.
MoherDShamseerLClarkeM, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev2015; 4: 1.
25.
SuhsKWPapanagiotouPHeinK, et al. Disease activity and conversion into multiple sclerosis after optic neuritis is treated with erythropoietin. Int J Mol Sci2016; 17(10): 1666.
26.
Borhani-HaghighiAGhodsiMRazeghinejadMR, et al. Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event. Neurosciences (Riyadh)2012; 17(2): 151–155.
27.
FoxEJRhoadesRW.New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol2012; 25(Suppl): S11–S19.
28.
HigginsJPAltmanDGGotzschePC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. Br Med J2011; 343: d5928.
29.
TsivgoulisGKatsanosAHGrigoriadisN, et al. The effect of disease modifying therapies on disease progression in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS One2015; 10(12): e0144538.
30.
SackettDL.Evidence-based medicine and treatment choices. Lancet1997; 349(9051): 570; author reply 2-3.
BeroLA.Why the cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev2013; (12): ED000075.
33.
SterneJASuttonAJIoannidisJP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J2011; 343: d4002.
34.
EggerMDavey SmithGSchneiderM, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J1997; 315(7109): 629–634.
35.
BorensteinM.Software for publication bias. In: RothsteinHRSuttonAJBorensteinM (eds) Publication Bias in Meta-Analysis – Prevention, Assessment and Adjustments. London, UK: Wiley, 2005, pp. 193–220.
36.
MetzLMLiDKBTraboulseeAL, et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med2017; 376(22): 2122–2133.
37.
MillerAEWolinskyJSKapposL, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2014; 13(10): 977–986.
38.
O’ConnellKKellySKinsellaK, et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial. Trials2013; 14: 272.
39.
ComiGMartinelliVRodegherM, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler2013; 19(8): 1074–1083.
40.
WaubantEPelletierDMassM, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology2012; 78(15): 1171–1178.
41.
ComiGMartinelliVRodegherM, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet2009; 374(9700): 1503–1511.
42.
LeistTPComiGCreeBA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol2014; 13(3): 257–267.
43.
HonceJMNairKVSillauS, et al. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology2019; 92(7): e723–e732.
44.
FreedmanMSLeistTPComiG, et al. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin2017; 3(4): 2055217317732802.
45.
ComiGDe StefanoNFreedmanMS, et al. Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry2017; 88(4): 285–294.
46.
De StefanoNComiGKapposL, et al. Efficacy of subcutaneous interferon beta-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry2014; 85(6): 647–653.
47.
DiemRMolnarFBeisseF, et al. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open2016; 6(3): e010956.
48.
RaftopoulosRHickmanSJToosyA, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol2016; 15(3): 259–269.
49.
McKeeJBElstonJEvangelouN, et al. Amiloride clinical trial in optic neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial. BMJ Open2015; 5(11): e009200.
50.
SergottRCBennettJLRieckmannP, et al. ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. J Neurol Sci2015; 351(1–2): 174–178.
51.
DerakhshandiHEtemadifarMFeiziA, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg2013; 113(3): 257–263.
52.
TsakiriAKallenbachKFugloD, et al. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler2012; 18(1): 72–81.
53.
Medicine CgIBMNLo. A prospective study looking at the use of rebif in subjects with clinically isolated syndrome (CIS-ON). 2006. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT 02254304, A prospective study looking at the use of rebif in subjects with clinically isolated syndrome (CIS-ON); 2018, March 30. http://clinicaltrials.gov/ct2/show/study/NCT02254304
54.
JacobsLDBeckRWSimonJH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med2000; 343(13): 898–904.
55.
McKeeJBCottriallCLElstonJ, et al. Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial. Mult Scler2019; 25(2): 246–255.
56.
FarciRCartaACoccoE, et al. Optical coherence tomography angiography in multiple sclerosis: a cross-sectional study. PLoS One2020; 15(7): e0236090.
57.
SchinzelJSchwarzloseLDietzeH, et al. Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial. Trials2012; 13: 94.
58.
FlacheneckerP.Disease-modifying drugs for the early treatment of multiple sclerosis. Expert Rev Neurother2004; 4(3): 455–463.
59.
La MantiaLVacchiLRovarisM, et al. Interferon beta for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry2013; 84(4): 420–426.
60.
FilippiniGMunariLIncorvaiaB, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet2003; 361(9357): 545–552.
61.
WingerchukDMWeinshenkerBG.Disease modifying therapies for relapsing multiple sclerosis. Br Med J2016; 354: i3518.
62.
MerkelBButzkuevenHTraboulseeAL, et al. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev2017; 16(6): 658–665.
63.
ClericoMFaggianoFPalaceJ, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev2008; (2): CD005278.
64.
BritzeJPihl-JensenGFrederiksenJL.Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol2017; 264(9): 1837–1853.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
